Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BRII-297 in Healthy Adults
NCT05845840Phase 1Completed
- Sponsor
- Brii Biosciences
- Start
- May 2023
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in postpartum depression (PPD) comparing BRII-297 with Placebo (2 arms). Primary endpoints: Number of participants with adverse events, Number of participants with abnormal clinical vital signs and 11 more. Started May 2023; status: completed.
02
Drugs
BRII-297
03
Conditions
postpartum depression (PPD)
Beyond the preview
Go deeper on NCT05845840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05845840.